Introduction of Immunoscore for Colon Cancer Prediction

Research Development

An international team of researchers has introduced the “Immunoscore,” a novel tool designed to predict the likelihood of colon cancer recurrence. Their findings were published in the esteemed journal, The Lancet. For many cancer survivors, the question, “Will it come back?” remains a pressing concern. Until recently, existing tests for predicting colon cancer recurrence offered only moderate accuracy.

Identifying Key Immune Cells

To enhance prediction methods, researchers focused on a specific type of immune cell known as cytotoxic T cells. These cells have the ability to eliminate cancer cells, and their presence within tumors has been considered a positive indicator since the early 1900s. Numerous scientific studies have suggested that the activity of immune cells can provide insights into the potential for tumor recurrence.

The Development and Validation of Immunoscore

Collaboration with the Society for Immunotherapy of Cancer

In 2012, a collaborative effort with the Society for the Immunotherapy of Cancer aimed to create the Immunoscore scoring system. An international cohort of researchers evaluated the effectiveness of this system in predicting recurrence risk among colon cancer patients.

Study Methodology and Findings

The study analyzed tumor samples from 2,681 colon cancer patients. Utilizing specialized computer software, the density of two types of T cells was measured. Patients were monitored for an average of five years, revealing that those with a high Immunoscore exhibited the lowest recurrence risk at the five-year mark.

Significance of Immunoscore in Cancer Treatment

Global Participation and Consistent Results

The study involved fourteen research centers worldwide, all of which reported similar outcomes. The Immunoscore demonstrated superior performance compared to existing recurrence tests, thus validating its clinical utility.

Broader Implications of Immunoscore

The authors of the study noted that the Immunoscore could also identify tumors with a higher chance of metastasis. Additionally, there is potential for the scoring system to serve as an indicator of a patient’s response to immunotherapy or chemotherapy.

Future Directions

Proposed Classification System

The researchers advocate for the incorporation of the Immunoscore into a new classification system for cancers, marking a pioneering approach by basing cancer classification on immune system activity.

References

1. Pagès F, Mlecnik B, Marliot F, et al. International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. Lancet. 2018. doi:10.1016/S0140-6736(18)30789-X
2. Sidaway P. Immunoscore provides a more accurate prognosis. Nat Rev Clin Oncol. 2018. doi:10.1038/s41571-018-0050-y.